Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Here’s a recap of companies announcing facility expansions this past month and life sciences job creations across the nation.
He will be replaced on an interim-basis by Thomas McCourt, who currently serves as company president.
James C. Mullen succeeds Cynthia Collins as Editas’ CEO, effective on February 15, 2021.
A Portland, Oregon biotech consultant is facing two counts of insider trading charges, with federal prosecutors and securities regulators claiming the defendant made profitable stock trades using confidential information he learned during his time consulting for Abeona Therapeutics.
The duo launch Riverway Discoveries to drive the development and commercialization of new cancer therapeutics faster into patient’s hands.
The combined company will be called Gemini Therapeutics, Inc. and will trade under the ticker symbol, GMTX.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
Over the course of 2020, Sanofi saw significant growth in its specialty care sales primarily driven by its blue-chip asset, Dupixent, as well as an increase in vaccine sales that were driven by demand for differentiated influenza vaccines, the company announced in its year-end financial report.
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.